docosanol
Trade name: abreva
Approved
Jul 25, 2000
Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV. Used for the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters). — NCATS
Clinical trial activity
3 trials · 4 clinical orgs · 7 marketing orgs
Earliest trial started Apr 17, 2007 (NCT00467662)
Timeline
2000s
- Jul 25, 2000
Avanir — Earliest FDA Approval
- Jul 25, 2000
Avanir — NDA Organization
- Jul 25, 2000
GlaxoSmithKline — Marketing Organization
- Jul 25, 2000
GlaxoSmithKline — NDA Secondary Org
2010s
- Nov 19, 2018
Actavis — Marketing Organization
- Nov 19, 2018
P&L Development — Marketing Organization
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
2020s
- May 3, 2022
Alembic — Marketing Organization
- Oct 7, 2022
Encube Ethicals Pvt. Ltd. — Marketing Organization
- Oct 26, 2023
Taro Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
- Envelope glycoproteinINHIBITOR
Envelope glycoprotein inhibitor
Seems to prevent the fusion between the host membrane and lipid-enveloped virus.
- Envelope glycoprotein D (gD) ↗
- Envelope glycoprotein B (gB) ↗
- Envelope glycoprotein C (gC) ↗
- Envelope glycoprotein E (gE) ↗
- Envelope glycoprotein G (gG) ↗
- Envelope glycoprotein H (gH) ↗
- Envelope glycoprotein I (gI) ↗
- Envelope glycoprotein J (gJ) ↗
- Envelope glycoprotein K (gK) ↗
- Envelope glycoprotein L (gL) ↗
- Envelope glycoprotein M (gM) ↗
- Envelope glycoprotein N (gN) ↗
Approval history
- approvedJul 25, 2000
Chemistry & pharmacology
SMILES
CCCCCCCCCCCCCCCCCCCCCCO- Mol. weight
- 326.6 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaDocosanol ↗
- NCATS9G1OE216XY ↗
- ChEMBLCHEMBL1200453 ↗
Also known as
- 1-docosanol
- 1-docosanol
- 1-docosanol
- 1-docosanol
- abreva
- abreva
- abreva
- abreva
- abreva
- behenic alcohol
- behenic alcohol
- behenic alcohol
- behenyl alcohol
- behenyl alcohol
- behenyl alcohol
- behenyl alcohol
- behenyl alcohol
- docosan-1-ol
- docosan-1-ol
- docosanol
- docosanol
- docosanol
- docosanol
- docosanol
- docosanol
- docosanol
- docosanol
- docosanol
- docosanol
- docosanol
- docosyl alcohol
- docosyl alcohol
- docosyl alcohol
- ik.2
- lidakol
- lidakol
- n-docosanol
- n-docosanol
- n-docosanol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04893577 | Phase 2 | Nov 30, 2021 | University of Utah |
| NCT03977792 | Phase 2 | Jul 31, 2019 | Ecogene 21, Laboratoire Boreaderme Inc. |
| NCT00467662 | Phase 4 | Apr 17, 2007 | Hebrew University |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ecogene 21 | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Laboratoire Boreaderme Inc. | For profit | 1 | 1 | 1 | 2019 |
| University of Utah | Academic/Hospital | 1 | 1 | 1 | 2021 |
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Actavis | For profit | MKTG | Nov 19, 2018 |
| Alembic | For profit | MKTG | May 3, 2022 |
| Alembic | For profit | SYN | May 3, 2022 |
| Avanir | For profit | NDA | Jul 25, 2000 |
| Encube Ethicals Pvt. Ltd. | For profit | MKTG | Oct 7, 2022 |
| GlaxoSmithKline | For profit | MKTG | Jul 25, 2000 |
| GlaxoSmithKline | For profit | NDA2 | Jul 25, 2000 |
| P&L Development | For profit | MKTG | Nov 19, 2018 |
| Taro Pharmaceuticals | For profit | MKTG | Oct 26, 2023 |